Polycystic Ovary Syndrome and the Role of Metformin in Ovulation Induction

作     者：Fabiana Fraga Gabriel Azeredo César Salgado Romeiro Larissa Bianca Paiva Cunha de Sá Alberto Krayyem Arbex 

作者机构：Endocrinology Division IPEMED Medical School Sã o Paulo Brazil Internal Medicine Division Itajubá  Brazil Diabetology Department Malteser Krankenhaus St. Franziskus Hospital Flensburg Germany Harvard T. H. Chan School of Public Health Boston MA USA 

出 版 物：《Health》 (健康（英文）)

年 卷 期：2018年第10卷第5期

页      面：565-576页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Polycystic Ovary Syndrome Metformin Oral Contraceptives Fertility Anovulation 

摘      要：The Polycystic Ovary Syndrome (PCOS) is frequently associated with comorbidities such as obesity, reduced glucose tolerance, hypertension, macrovascular disease and dyslipidemia. The Metabolic syndrome occurs in 30% of women with PCOS. Metformin has increasingly been used in this therapy due to its effects in reducing insulin resistance. Treatment of PCOS aims to reduce the symptoms of hyperandrogenism, regularize the menstrual cycle, reduce metabolic abnormalities, and lower the risk of type 2 diabetes mellitus and of cardiovascular disease. Additionally it is important to prevent hyperplasia and endometrial cancer, and to offer contraception to those who do not wish pregnancy, and to help to induce ovulation to those who do. The effectiveness of metformin in this treatment is assessed in the light of the current best evidence.